ACAD
39.46
+0.33
+0.84%
AEMD
7.61
-0.12
-1.55%
APRI
1.76
+0.15
+9.32%
ARNA
2.74
-0.01
-0.36%
ATEC
0.58
-0.01
-1.69%
CNAT
3.84
-0.01
-0.26%
CRXM
0.35
+0.01
+2.94%
CYTX
0.357
-0.013
-3.4865%
DXCM
88.31
+0.3
+0.34%
GNMK
9.58
+0.07
+0.74%
HALO
16.89
+0.04
+0.24%
ILMN
193.16
-2.29
-1.17%
INNV
0.101
+0.00
+0.0990%
INO
7.11
+0.02
+0.28%
ISCO
3.5
-0.08
-2.23%
ISIS
52.1
+0.53
+1.03%
LGND
89.85
+0.91
+1.02%
LPTN
0.26
+0.01
+4.00%
MBVX
1.6
-0.05
-3.03%
MEIP
1.85
-0.06
-3.14%
MNOV
3.15
-0.01
-0.32%
MRTX
25.85
-0.13
-0.50%
MSTX
0.469
-0.001
-0.213%
NBIX
48.55
+0.46
+0.96%
NUVA
51.21
-0.48
-0.93%
ONCS
5.85
+0.04
+0.69%
ONVO
2.53
+0.03
+1.20%
OREX
2.64
-0.11
-4.00%
OTIC
22.1
+0.54
+2.50%
QDEL
20.87
+0.11
+0.53%
RCPT
231.96
0.00
0.00%
RGLS
8.63
+0.18
+2.13%
RMD
51.17
-0.46
-0.89%
SCIE
0.014
0.00
0.00%
SPHS
0.84
0.00
0.00%
SRNE
12.88
+0.17
+1.34%
TROV
5.85
-0.09
-1.52%
VICL
0.605
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
19.76
+0.13
+0.66%
ACAD
39.46
+0.33
+0.84%
AEMD
7.61
-0.12
-1.55%
APRI
1.76
+0.15
+9.32%
ARNA
2.74
-0.01
-0.36%
ATEC
0.58
-0.01
-1.69%
CNAT
3.84
-0.01
-0.26%
CRXM
0.35
+0.01
+2.94%
CYTX
0.357
-0.013
-3.4865%
DXCM
88.31
+0.3
+0.34%
GNMK
9.58
+0.07
+0.74%
HALO
16.89
+0.04
+0.24%
ILMN
193.16
-2.29
-1.17%
INNV
0.101
+0.00
+0.0990%
INO
7.11
+0.02
+0.28%
ISCO
3.5
-0.08
-2.23%
ISIS
52.1
+0.53
+1.03%
LGND
89.85
+0.91
+1.02%
LPTN
0.26
+0.01
+4.00%
MBVX
1.6
-0.05
-3.03%
MEIP
1.85
-0.06
-3.14%
MNOV
3.15
-0.01
-0.32%
MRTX
25.85
-0.13
-0.50%
MSTX
0.469
-0.001
-0.213%
NBIX
48.55
+0.46
+0.96%
NUVA
51.21
-0.48
-0.93%
ONCS
5.85
+0.04
+0.69%
ONVO
2.53
+0.03
+1.20%
OREX
2.64
-0.11
-4.00%
OTIC
22.1
+0.54
+2.50%
QDEL
20.87
+0.11
+0.53%
RCPT
231.96
0.00
0.00%
RGLS
8.63
+0.18
+2.13%
RMD
51.17
-0.46
-0.89%
SCIE
0.014
0.00
0.00%
SPHS
0.84
0.00
0.00%
SRNE
12.88
+0.17
+1.34%
TROV
5.85
-0.09
-1.52%
VICL
0.605
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
19.76
+0.13
+0.66%
Home » Archive by Category

Syndication

Web Designer at Onward Search (San Diego, CA)

February 18, 2015 – 9:35 am

Our client, a growing biotech company, is seeking a Web Designer with strong design skills and front-end web development abilities. This is a great long-term contract in San Diego through the end of 2015! You are detail oriented,…

Neurocrine holds $225M offering

February 18, 2015 – 9:33 am

San Diego biotech says proceeds to fund research, development and commercialization.

Su Lab: BioGPS Featured Article – Identification of Novel Tumor-Associated Cell Surface Sialoglycoproteins in Human Glioblastoma Tumors Using Quantitative Proteomics

February 18, 2015 – 8:00 am

BioGPS has become the valuable resource that it is because of the contributions from our wonderful user community. Thank you… More…

Dance Biopharm Completes $9.5 Million Private Financing

February 18, 2015 – 7:00 am

–Total Funds Raised to Date Exceed $33 Million–

BRISBANE, Calif., Feb. 18, 2015 /PRNewswire/ — Dance Biopharm Inc. (Dance), a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the completion of a $9.5 million convertible note and warrants financing. SternAegis Ventures, through Aegis Capital Corp., acted as the exclusive placement agent for this offering. Participants in the financing include a syndicate of individual and institutional investors, the majority of whom are focused on the biotechnology and healthcare sectors. The proceeds of the private placement will be used principally to fund human clinical studies, manufacture drug and devices for clinical studies, and for working capital and general corporate purposes.

“This additional capital is important as we continue to prepare for more clinical trials for Dance 501, our inhaled insulin product candidate for diabetes, and we are delighted to have had SternAegis Ventures enable this successful and efficient financing,” stated Dr. John Patton, chairman and chief executive officer of Dance. 

About Dance 501, a Next-Generation Inhaled Insulin Product
Dance 501 consists of a high purity liquid formulation of recombinant human insulin stored in a dispenser for administration with a small handheld electronic inhaler. The electronic inhaler utilizes a patented vibrating mesh technology, designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few comfortable breaths.

Diabetes, a Global Epidemic Affecting an Estimated 382 Million People Worldwide
In its 2013 report, the International Diabetes Federation (IDF), estimated that approximately 382 million people worldwide suffer from diabetes. The IDF further estimated that global health expenditures attributed to the treatment of adult patients with diabetes was $548 billion in 2013. Type 2 diabetes accounts for 85 to 95 percent of all diabetes worldwide. According to the IDF, the number of patients with diabetes is expected to grow to approximately 592 million in less than 25 years. For most patients with diabetes, the disease leads to serious medical complications.

The long-term benefits of mealtime insulin therapy have been consistently demonstrated. Many clinical studies have shown that insulin is not only the most effective therapy for controlling blood glucose, but insulin also preserves pancreatic function to reduce disease progression. Although injected insulin is the gold standard for treatment, traditionally it has been the last drug taken by Type 2 patients. The typical patient delays taking mealtime insulin for five to ten years in order to avoid multiple daily injections. Delaying insulin treatment, or refusing to take injections, eventually results in negative health consequences for the patients and enormous costs to health care systems. Now all of the major diabetes medical associations recommend the introduction of insulin earlier in the treatment process for Type 2 patients and continued use of insulin by Type 1 patients.

About Dance Biopharm Inc.
Dance Biopharm is a privately-held company based in the San Francisco Bay Area focused on the clinical development of inhaled insulin products to treat diabetes patients worldwide. The company began operations in 2010, founded by Dr. John Patton, who has over 25 years of experience developing inhaled insulin and other inhaled therapies. The Dance team consists of experts in all aspects of inhaled insulin development, and the company is dedicated to creating a new generation of products that will allow inhaled insulin to transform the treatment of diabetes. Additional information about Dance Biopharm can be found at www.dancebiopharm.com.

FORWARD-LOOKING STATEMENTS
All statements other than statements of historical fact included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. We have based these forward-looking statements upon information available to management as of the date of this release and management’s expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to our limited operating history, our ability to successfully develop Dance 501, the cost and uncertainty of obtaining regulatory approvals, and changes in the competitive or regulatory landscape.

Contact:
Cook Williams Communications, Inc.
Jennifer Williams
jennifer@cwcomm.org
(360) 668-3701

 

SOURCE Dance Biopharm

Medical Device Assembler (Sorrento Valley)

February 18, 2015 – 6:43 am

Minimum 1 year experience with GMP medical device manufacturing and completing device records, attention-to-detail, focused and productive, reliable, independent-requiring minimal supervision once trained, effective communicator and confident. The po […

aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris™ in FSHD

February 18, 2015 – 6:12 am

SAN DIEGO, Feb. 18, 2015 /PRNewswire/ — aTyr Pharma, Inc. (“aTyr”), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today the European Commission (EC) has granted orphan drug designation to Resolaris™ for the treatment of facioscapulohumeral muscular dystrophy (FSHD).  Resolaris™, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic, is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

“Our mission is to develop medicines that will make a meaningful difference to patients impacted by debilitating rare diseases.  We are very pleased that the EMA has recognized the potential of Resolaris™ for patients suffering from FSHD,” said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma.  “The Agency’s decision is an important advancement for our promising Physiocrine-based medicines, and marks a key milestone in our strategy to deliver Resolaris™ to address the unmet needs of patients with this rare disease.”

aTyr previously announced the first patient study of Resolaris™ in adults with FSHD, a rare and severe genetic myopathy for which there are currently no approved treatments.  The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients currently enrolling at multiple sites in the European Union (EU).

EMA orphan designation is intended to encourage development of medicines for the diagnosis, treatment, or prevention of life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU.  Medicines that receive orphan designation are eligible for a number of incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized.  Orphan designation is conferred following a positive opinion by the EMA’s Committee for Orphan Medicinal Products (COMP).

About Resolaris
aTyr Pharma is developing Resolaris™ as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.  Resolaris™ is derived from a naturally occurring protein released in vitro by human skeletal muscle cells, and received orphan product designation in the EU for the treatment of FSHD.  aTyr believes Resolaris™ will provide therapeutic benefit to patients with rare myopathies with an immune component characterized by excessive immune cell involvement.

About Physiocrines
Physiocrines comprise naturally occurring proteins that aTyr believes promote homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. Physiocrines are extracellular signaling regions of tRNA synthetases, an ancient family of enzymes that catalyze a key step in protein synthesis.  aTyr is currently focused on Physiocrines that act as endogenous modulators of the immune system.  Physiocrines offer the opportunity for modulating biological pathways through newly discovered, naturally occurring mechanisms, which may provide advantages over engineered immuno-modulatory therapeutics, including the potential for improved patient outcomes and reduced side effect profiles.

About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.  To protect this pipeline, aTyr built an intellectual property estate comprising 13 patents and over 200 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr’s key programs are currently focused on severe, rare diseases characterized by immune dysregulation, for which there are currently limited or no treatment options.  The privately held biotech was founded by Professors Paul Schimmel and Xiang-Lei Yang, two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute, and investors include Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners.  For more information, please visit http://www.atyrpharma.com

 

SOURCE aTyr Pharma

Aegis Awarded U.S. Patent No. 8,927,497 for Non-Invasive Delivery of Anti-Seizure Drugs

February 18, 2015 – 6:01 am

SAN DIEGO, CA–(Marketwired – Feb 18, 2015) – Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,927,497 providing broad coverage for non-invasive delivery of anti-seizure drugs via a simple metered nasal spray. The rapidly acting formulations utilize Aegis’ patented Intravail® transmucosal absorption enhancer technology.

Decoy protein stops all tested HIV strains

February 18, 2015 – 5:00 am

Scripps Research-led genetic engineering feat jams HIV’s infection mechanism.

New Insights into 3D Genome Organization and Genetic Variability

February 18, 2015 – 5:00 am

While genomics is the study of all of the genes in a cell or organism, epigenomics is the study of all the genomic add-ons and changes that influence gene expression but aren’t encoded in the DNA sequence. A variety of new epigenomic information is now available in a collection of studies published Feb. 19 in Nature by the National Institutes of Health (NIH) Roadmap Epigenomics Program.

Payroll-Benefits – Transition Staffing Group, Inc – San Diego, CA

February 18, 2015 – 3:10 am

Experience working in the biotechnology industry is preferred. We are currently in need of a talented Payroll and Benefits professional…. $55,000 a year
From Transition Staffing Group, Inc – 18 Feb 2015 10:10:27 GMT
– View al…